Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 14Other solid neoplasm 13Tumor-Agnostic 8Thoracic 3Dermatologic 3Other hematologic neoplasm 2Sarcoma 1Plasma cell 1Other neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 3Neoplasms 2

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Rifampin × Dermatologic × Clear all
NCT02608034 2020-02-12

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Genentech, Inc.

Phase 1 Completed
32 enrolled
Dermatologic

Melanoma

NCT01954043 2017-11-14

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

GlaxoSmithKline

Phase 1 Completed
23 enrolled
Dermatologic

Melanoma, Neoplasms

NCT01765543 2016-12-15

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

Hoffmann-La Roche

Phase 1 Completed
27 enrolled 16 charts
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡